Acquisition - January 3, 2017
SCA to acquire BSN Medical
SCA has entered into an agreement to acquire BSN medical, a medical solutions company, from the private equity group EQT. BSN medical develops, manufactures, markets and sells products within wound care, compression therapy and orthopedics. The purchase price amounts to EUR 2,740m on a debt- and cash-free basis. The completion of the transaction is subject […]
Acquisition - January 3, 2017
AGC Asahi Glass acquires CMC Biologics
Danish CDMO CMC Biologics and AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, have entered into a definitive agreement with CMC Biologics’ shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100% of CMC Biologics’ shares. “With the high level of growth and […]
Acquisition - November 2, 2016
Karo Pharma acquires BioPhausia
Medivir has entered into an agreement with Karo Pharma regarding the sale of its subsidiary BioPhausia. The purchase price will be SEK 908 million on a cash and debt free basis, including a normalized working capital an the transaction is expected to close by mid-December 2016. As previously communicated the Board of Directors of Medivir tasked […]
Acquisition - October 31, 2016
GE raises bid for Arcam
General Electric on Thursday raised its recommended bid for Arcam to value the Swedish 3D printer maker at 6.2 billion crowns ($696 million), a day after abandoning its planned takeover of Germany’s SLM Solutions. GE lifted its bid to 300 crowns per share from 285 crowns. The U.S. industrial conglomerate, one of Arcam’s largest customers, […]
Acquisition - October 4, 2016
AZ enters agreement with Cilag
AstraZeneca has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US. Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis (inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling […]
Acquisition - August 25, 2016
AZ sells antibiotics business to Pfizer
AstraZeneca has announced that it has entered into an agreement with Pfizer to sell the commercialisation and development rights to its late-stage small molecule antibiotics business in most markets globally outside the US. Under the terms of the agreement, Pfizer will make an upfront payment to AstraZeneca of $550 million upon completion and a further […]
